---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010507"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:33.678006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Olema reports preliminary cash >$500M as of Dec 31, 2025

## Summary
- Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).
- No other financial results disclosed; annual 10-K filing pending.
- Investor presentation posted on company website as of January 12, 2026.
- Cash position provides runway for ongoing breast cancer pipeline development.

## SEC filing metadata
- accession: 0001193125-26-010507
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/0001193125-26-010507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526010507/olma-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010507
- JSON: https://secwatch.observer/filing/0001193125-26-010507.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.